#ERS26: Generate:Biomedicines discloses early respiratory drug data after poster leaknews2026-08-27T11:16:56+00:00August 27th, 2026|Endpoints News|
Cellares rebukes Bristol Myers’ criticism of its cell therapy technologynews2026-08-26T17:40:31+00:00August 26th, 2026|Endpoints News|
MassBio report details challenges spanning China, NIHnews2026-08-26T17:28:41+00:00August 26th, 2026|Endpoints News|
Biohaven strikes $795M deal for commercial partner in epilepsynews2026-08-26T17:07:48+00:00August 26th, 2026|Endpoints News|
Haisco grants license to Sentivera; ViiV’s HIV treatment OK’d for newbornsnews2026-08-26T15:16:11+00:00August 26th, 2026|Endpoints News|
FDA approves Revolution Medicines’ pancreatic cancer drugnews2026-08-26T15:15:20+00:00August 26th, 2026|Endpoints News|
An uncertain future for Aurora, the first startup dedicated to custom CRISPR therapiesnews2026-08-26T14:24:29+00:00August 26th, 2026|Endpoints News|
Akeso, Summit hail ivonescimab’s biliary tract cancer win in China-only Phase 3 trialnews2026-08-26T11:02:44+00:00August 26th, 2026|Endpoints News|
Exclusive: Faro raises $37M Series B to speed up clinical trials with AInews2026-08-26T11:00:59+00:00August 26th, 2026|Endpoints News|
Spyre drops rheumatoid arthritis hopes for anti-TL1A drug after modest Phase 2 datanews2026-08-26T11:00:53+00:00August 26th, 2026|Endpoints News|
